EP3535417B1 - Détection précoce de stades préliminaires de tumeurs de cellules germinales testiculaires - Google Patents

Détection précoce de stades préliminaires de tumeurs de cellules germinales testiculaires Download PDF

Info

Publication number
EP3535417B1
EP3535417B1 EP17800438.8A EP17800438A EP3535417B1 EP 3535417 B1 EP3535417 B1 EP 3535417B1 EP 17800438 A EP17800438 A EP 17800438A EP 3535417 B1 EP3535417 B1 EP 3535417B1
Authority
EP
European Patent Office
Prior art keywords
mir
pcr
tin
cdna
batch
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP17800438.8A
Other languages
German (de)
English (en)
Other versions
EP3535417A1 (fr
EP3535417B9 (fr
Inventor
Meike SPIEKERMANN
Nina WINTER
Gazanfer Belge
Arlo RADTKE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mirdetect GmbH
Original Assignee
Mirdetect GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mirdetect GmbH filed Critical Mirdetect GmbH
Publication of EP3535417A1 publication Critical patent/EP3535417A1/fr
Publication of EP3535417B1 publication Critical patent/EP3535417B1/fr
Application granted granted Critical
Publication of EP3535417B9 publication Critical patent/EP3535417B9/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Definitions

  • the present invention relates to methods of detecting preliminary stages of testicular germ cell tumors, more particularly testicular intraepithelial neoplasia (TIN), in a subject and to the use of miR-371a-3p as a biomarker for the detection of TIN. It further relates to the use of miR-371a-3p-specific primers and/or miR-371a-3p-specific probes and of corresponding kits for the detection of TIN.
  • TIN testicular intraepithelial neoplasia
  • Testicular germ cell cancer is the most frequently occurring cancer in young men aged between 20 and 45. With early detection, appropriate treatment and close monitoring, the chances of recovery from testicular cancer are very good, although the long-term effects of treatment and monitoring are immense, and the risk of re-developing testicular cancer or suffering a relapse may be up to 31% depending on the tumor type and stage.
  • the known risk factors for the development of testicular cancer include family history and undescended testicles (cryptorchidism), which increases the risk of developing testicular cancer four-fold.
  • Testicular germ cell cancer arises from the precursor lesion "germ cell neoplasia in situ (GCNIS)", also referred to as “carcinoma in situ (CIS)", “intratubular germ cell neoplasia, unclassified (IGCNU)” and “testicular intraepithelial neoplasia (TIN)” ( Berney D.M. et al., 2016, Histopathology 69(1):7-10 ; Moch H. et al., 2016, Eur Urol 70(1):93-105 ).
  • TIN is the uniform precursor of testicular germ cell tumors and it may be present in a testicle years before testicular germ cell cancer becomes invasive ( Dieckmann K.P.
  • the present invention relates to a method of detecting testicular intraepithelial neoplasia (TIN) in a subject, the method comprising determining the expression level ofmiR-371a-3p in a biological sample from the subject, wherein the expression level of miR-371a-3p is indicative of the presence or absence of TIN in the subject.
  • TIN testicular intraepithelial neoplasia
  • the method comprises the steps of:
  • the method comprises the steps of:
  • an expression level of miR-371a-3p which is increased as compared to a control, is indicative of the presence of TIN in the subject.
  • an expression level of miR-371a-3p which is higher than a predefined cut-off value, is indicative of the presence of TIN in the subject.
  • the biological sample is selected from the group consisting of body fluid, tissue, cells, cell lysate and cell culture supernatant.
  • the body fluid is selected from the group consisting of blood serum, blood plasma, seminal plasma, hydrocele fluid, spermatocele fluid, whole blood, urine, amniotic fluid, exudate, sputum, saliva and cerebrospinal fluid.
  • the body fluid is blood serum.
  • the tissue is selected from the group consisting of native tissue, snap-frozen tissue and formalin-fixed and paraffin-embedded (FFPE) tissue.
  • FFPE paraffin-embedded
  • step (ii) three aliquots of batch A are provided in step (ii).
  • the PCR-based approach is quantitative real-time PCR (qRT-PCR) or digital PCR (dPCR).
  • qRT-PCR quantitative real-time PCR
  • dPCR digital PCR
  • the present invention relates to the use of miR-371a-3p as a biomarker for the detection of testicular intraepithelial neoplasia (TIN).
  • TIN testicular intraepithelial neoplasia
  • miR-371a-3p is used as a body fluid-based biomarker, wherein, preferably, the body fluid is as defined above.
  • miR-371a-3p is used as a blood-based biomarker, in particular a blood serum-based biomarker.
  • the present invention relates to the use of at least one miR-371a-3p-specific primer and/or a miR-371a-3p-specific probe for the detection of testicular intraepithelial neoplasia (TIN).
  • TIN testicular intraepithelial neoplasia
  • the present invention relates to at least one miR-371a-3p-specific primer and/or a miR-371a-3p-specific probe for use in a method of detecting testicular intraepithelial neoplasia (TIN), wherein, preferably, the method is as defined above.
  • TIN testicular intraepithelial neoplasia
  • the present invention relates to the use of a kit comprising at least one miR-371a-3p-specific primer and/or a miR-371a-3p-specific probe for the detection of testicular intraepithelial neoplasia (TIN).
  • TIN testicular intraepithelial neoplasia
  • the kit further comprises means for isolating RNA from a biological sample and/or means for converting the RNA isolated from the biological sample into cDNA.
  • the biological sample is a body fluid as defined above.
  • the body fluid is blood serum.
  • the present invention relates to a kit as defined above for use in a method of detecting testicular intraepithelial neoplasia (TIN), wherein, preferably, the method is as defined above.
  • TIN testicular intraepithelial neoplasia
  • the present invention relates to a method of treating testicular intraepithelial neoplasia (TIN) in a subject or of preventing testicular cancer, more particularly testicular germ cell cancer, in a subject, the method comprising (i) detecting TIN in the subject by a method as defined above and (ii) providing therapy to the subject, wherein, preferably, the therapy is radiotherapy, orchiectomy and/or chemotherapy.
  • TIN testicular intraepithelial neoplasia
  • the terms used herein are defined as described in " A multilingual glossary of biotechnological terms (IUPAC Recommendations)", H.G.W. Leuenberger, B. Nagel, and H. Kölbl, Eds., Helvetica Chimica Acta, CH-4010 Basel, Switzerland, (1995 ).
  • Testicular intraepithelial neoplasia is a precursor lesion for testicular germ cell tumors and is also known as "germ cell neoplasia in situ (GCNIS)", “carcinoma in situ (CIS)” or “intratubular germ cell neoplasia, unclassified (IGCNU)". These terms are used interchangeably in the context of the present invention.
  • GCNIS germ cell neoplasia in situ
  • CIS cancer in situ
  • ITCNU intratubular germ cell neoplasia, unclassified
  • miRNAs are short, highly conserved, non-coding RNAs, which play an important role in the complex network of gene regulation. They specifically bind to messenger RNAs (mRNAs) and control gene expression through regulation of mRNA stability and translation. Generally, miRNAs consist of 21 to 23 nucleotides.
  • miR-371a-3p as referred to herein, is human miR-371a-3p ( Homo sapiens, hsa).
  • hsa-miR-371a-3p has the (5'-3') sequence AAGUGCCGCCAUCUUUUGAGUGU (SEQ ID NO: 1).
  • expression level may refer to the relative expression level, i.e., the expression level of miR-371a-3p relative to the expression level(s) of one or more reference nucleic acid molecules (e.g., another miRNA, such as miR-93-5p), or to the absolute expression level, i.e., the actual amount of miR-371a-3p.
  • reference nucleic acid molecules e.g., another miRNA, such as miR-93-5p
  • determining the expression level of miR-371a-3p in a biological sample may be “determining the presence or absence of miR-371a-3p in a biological sample”.
  • the expression level (or the presence or absence) of miR-371a-3p in the biological sample is indicative of the presence, absence and/or extent/progression of TIN in a subject from which the biological sample is obtained.
  • an expression level of miR-371a-3p which is increased as compared to a control (e.g., the expression level of miR-371a-3p in a subject not having TIN), is indicative of the presence of TIN in the subject.
  • an expression level of miR-371a-3p which is higher than a predefined cut-off value, is indicative of the presence of TIN in the subject.
  • the relative quantity (RQ) of miR-371a-3p is determined, wherein, preferably, the cut-off value is 5.
  • nucleic acid molecule may be DNA or RNA.
  • DNA relates to a molecule, which comprises deoxyribonucleotide residues and is preferably entirely or substantially composed of deoxyribonucleotide residues.
  • Deoxyribonucleotide relates to a nucleotide, which lacks a hydroxyl group at the 2'-position of a ⁇ -D-ribofuranosyl group.
  • complementary DNA cDNA
  • cDNA refers to doublestranded DNA synthesized from an RNA template in a reaction catalyzed by the enzyme reverse transcriptase.
  • RNA relates to a molecule, which comprises ribonucleotide residues and is preferably entirely or substantially composed of ribonucleotide residues.
  • “Ribonucleotide” relates to a nucleotide with a hydroxyl group at the 2'-position of a ⁇ -D-ribofuranosyl group.
  • the methods described herein and used in accordance with the presence invention allow the detection of specific nucleic acid molecules, e.g., miR-371a-3p, at the lower detection limit.
  • the term "lower detection limit” refers to the lower detection limit provided by a PCR-based approach, such as quantitative real-time PCR (qRT-PCR) or digital PCR (dPCR).
  • the term "lower detection limit” means that the concentration of the specific nucleic acid molecule, e.g., miR-371a-3p, in the biological sample is ⁇ 1 ⁇ 10 -11 M, or ⁇ 1 ⁇ 10 -12 M, or ⁇ 1 ⁇ 10 -13 M, or ⁇ 1 ⁇ 10 -14 M, or ⁇ 1 ⁇ 10 -15 M, or ⁇ 1 ⁇ 10 -16 M.
  • the term "lower detection limit” means that the concentration of the specific nucleic acid molecule, e.g., miR-371a-3p, in the biological sample is between 1 ⁇ 10 -11 M and 1 ⁇ 10 -17 M, or 1 ⁇ 10 -12 M and 1 ⁇ 10 -17 M, or 1 ⁇ 10 -13 M and 1 ⁇ 10 -17 M, or 1 ⁇ 10 -14 and 1 ⁇ 10 -17 M, or 1 ⁇ 10 -15 and 1 ⁇ 10 -17 M, or 1 ⁇ 10 -16 and 1 ⁇ 10 -17 M.
  • the term “lower detection limit” means that the number of the specific nucleic acid molecules, e.g. miR-371a-3p molecules, in the biological sample is ⁇ 10000, or ⁇ 5000, or ⁇ 2500, or ⁇ 1000, or ⁇ 500, or ⁇ 250. In one embodiment, the term “lower detection limit” means that the number of the specific nucleic acid molecules in the biological sample is between 20 and 10000, or 20 and 5000, or 20 and 2500, or 20 and 1000, or 20 and 500, or 20 and 250.
  • the term “lower detection limit” means that the number of the specific nucleic acid molecules in the biological sample is between 50 and 10000, or 50 and 5000, or 50 and 2500, or 50 and 1000, or 50 and 500, or 50 and 250. In one embodiment, the term “lower detection limit” means that the number of the specific nucleic acid molecules in the biological sample is between 100 and 10000, or 100 and 5000, or 100 and 2500, or 100 and 1000, or 100 and 500, or 100 and 250.
  • the concentrations or numbers of the specific nucleic acid molecule(s) recited herein refer to the concentrations or numbers of the specific nucleic acid molecule(s) in batch A comprising cDNA isolated/obtained from the biological sample (wherein a specific RNA molecule is converted into the corresponding cDNA molecule). In one embodiment, the concentrations or numbers of the specific nucleic acid molecule(s) recited herein refer to the concentrations or numbers of the specific nucleic acid molecule(s) in the RNA isolated/extracted from the biological sample.
  • the independent PCR performed with each of the three or more aliquots in step (ii) of the methods according to the present invention is a preamplification PCR reaction.
  • Preferred biological samples in accordance with the present invention are selected from the group consisting of body fluid, tissue, cells, cell lysate and cell culture supernatant.
  • Preferred body fluids are selected from the group consisting of blood serum, blood plasma, seminal plasma, hydrocele fluid, spermatocele fluid, whole blood, urine, amniotic fluid, exudate, sputum, saliva and cerebrospinal fluid.
  • the body fluid is blood serum.
  • Tissues are preferably selected from the group consisting of native tissue, snap-frozen tissue and formalin-fixed and paraffin-embedded (FFPE) tissue.
  • FFPE paraffin-embedded
  • RNA e.g., total RNA or miRNA
  • Means and methods for the isolation (or extraction) of RNA, e.g., total RNA or miRNA, from a biological sample are known to a person skilled in the art and include commercially available kits, such as the RNeasy Mini Kit and the miRNeasy Mini Kit (both from Qiagen).
  • the step of converting the RNA into cDNA is preferably performed by reverse transcription (RT) using the enzyme reverse transcriptase.
  • RT reverse transcription
  • Means and methods for reverse transcription and synthesis of cDNA are known to the skilled person and include commercially available kits, such as the TaqMan ® microRNA RT Kit (Life Technologies/Thermo Fisher Scientific).
  • Preferred PCR-based approaches in accordance with the present invention are quantitative real-time PCR (qRT-PCR) and digital PCR (dPCR).
  • the qRT-PCR is fluorescence-based qRT-PCR comprising the use of a fluorescently labeled probe.
  • Suitable fluorescent reporter and quencher dyes/moieties are known to a person skilled in the art and include, but are not limited to the reporter dyes/moieties 6-FAM TM , JOE TM , Cy5 ® and Cy3 ® and the quencher dyes/moieties dabcyl, TAMRA TM and BHQ TM -1, -2 or -3.
  • Other suitable fluorescent dyes for use in fluorescence-based qRT-PCR include EvaGreen ® and SYBR ® Green.
  • the increase of fluorescence in the reaction is directly proportional to the increase of target amplificates.
  • dPCR is an alternate method to conventional qRT-PCR for absolute quantification and detection of nucleic acid molecules. dPCR works by partitioning a sample of DNA or cDNA into many individual, parallel PCR reactions; some of these reactions contain the target nucleic acid molecule (positive) while others do not (negative).
  • a single molecule can be amplified a million-fold or more.
  • dye-labeled probes are used to detect sequence-specific targets. When no target sequence is present, no signal accumulates.
  • the fraction of negative reactions is used to generate an absolute count of the number of target molecules in the sample, without the need for standards or endogenous controls.
  • At least one miR-371a-3p-specific primer may, for example, refer to a single miR-371a-3p-specific primer, such as a miR-371a-3p-specific primer with a particular hairpin structure (e.g., a stem loop primer), used for conversion of RNA into cDNA, and/or to a pair ofmiR-371a-3p-specific primers used for qRT-PCR.
  • a single miR-371a-3p-specific primer such as a miR-371a-3p-specific primer with a particular hairpin structure (e.g., a stem loop primer), used for conversion of RNA into cDNA, and/or to a pair ofmiR-371a-3p-specific primers used for qRT-PCR.
  • miR-371a-3-specific primers and probes are known to a person skilled in the art.
  • miR-371a-3p-specific primers and probes are also commercially available, e.g., from Life Technologies (Thermo Fisher Scientific, Carlsbad, CA, USA) and Applied Biosystems (Darmstadt, Germany).
  • kit refers to an article of manufacture comprising one or more containers and, optionally, a data carrier. Said one or more containers may be filled with one or more of the above mentioned means or reagents. Additional containers may be included in the kit that contain, e.g., diluents, buffers and further reagents such as dNTPs.
  • Said data carrier may be a non-electronical data carrier, e.g., a graphical data carrier such as an information leaflet, an information sheet, a bar code or an access code, or an electronical data carrier such as a floppy disk, a compact disk (CD), a digital versatile disk (DVD), a microchip or another semiconductor-based electronical data carrier.
  • the access code may allow the access to a database, e.g., an internet database, a centralized, or a decentralized database.
  • Said data carrier may comprise instructions for the use of the kit in the methods of the invention.
  • the data carrier may comprise a cut-off value or reference level for the expression level of miR-371a-3p. In case that the data carrier comprises an access code which allows the access to a database, said threshold value or reference level is deposited in this database.
  • the data carrier may comprise information or instructions on how to carry out the methods of the present invention.
  • the term "subject”, as used herein, relates to any organism such as a vertebrate, particularly any mammal, including both a human and another mammal, e.g., an animal such as a rodent, a rabbit, or a non-human primate (e.g., a monkey).
  • the rodent may be a mouse, rat, hamster, guinea pig, or chinchilla.
  • the subject is a male subject.
  • the subject is a human.
  • a subject is a subject with or suspected of having a disease or disorder, in particular a disease or disorder as defined herein, also designated “patient” herein.
  • the subject has a family history of testicular cancer and/or has or used to have undescended testicles (cryptorchidism).
  • the present invention also provides a method of treating TIN in a subject or of preventing testicular cancer, more particularly testicular germ cell cancer, in a subject, the method comprising (i) detecting TIN in the subject by a method as defined herein and (ii) providing therapy to the subject.
  • therapy preferably includes radiotherapy, in particular local radiotherapy, orchiectomy and/or chemotherapy.
  • local radiotherapy may involve 16-20 Gy in fractions of 2 Gy.
  • Radiotherapy may, for example, be performed in the case of a solitary testis.
  • Orchiectomy may, for example, be performed if the contralateral testis is healthy.
  • therapy may be preceded by monitoring of the subject, e.g., by regular testicular ultrasound.
  • RNA For quantification of miR-371a-3p in serum samples, 6 ⁇ l of total RNA were reverse transcribed using the TaqMan ® microRNA RT Kit (Life Technologies/Thermo Fisher Scientific) and a primer pool consisting of 1 ⁇ l each of the stem loop primers for miR-371a-3p and miR-93-5p (for normalization) (Life Technologies/Thermo Fisher Scientific, assay IDs: 002124 (miR-371a-3p) and 000432 (miR-93-5p)).
  • RNA/miRNA in serum Because of the low concentration of RNA/miRNA in serum, a preamplification step was performed prior to qRT-PCR.
  • the preamplification reaction consisted of 4 ⁇ l of the reverse transcription (RT) product, 1.12 ⁇ l assay (diluted 1:100) each of miR-371a-3p and miR-93-5p, 4 ⁇ l 5x Real Time ready cDNA Pre-Amp Master (Roche, Mannheim, Germany) and nuclease free water to add up to a total reaction volume of 20 ⁇ l.
  • Preamplification was performed at 95°C for 1 min, followed by 14 cycles of 95°C for 15 s and 60° C for 4 min.
  • the preamplification product was then diluted 1:2 in nuclease-free water and 5 ⁇ l of the diluted preamplification product were used for qRT-PCR.
  • the qRT-PCR reaction consisted of 10 ⁇ l of the FASTstart Universal Probe Master (Roche, Mannheim, Germany), 1 ⁇ l of the specific assay, and nuclease free water in a total reaction volume of 20 ⁇ l.
  • qRT-PCR was performed on the 7500 Fast Real-Time PCR System (Life Technologies/Thermo Fisher Scientific) with the following cycling conditions: 10 min at 95°C, then 40 cycles of 15 s at 95°C and 1 min at 60°C.
  • Relative quantity (RQ) was calculated using the ⁇ Ct method.
  • This phenomenon is due to the statistical distribution of the extremely small amount of miRNA molecules: if there are, for example, 1002 miRNA molecules compared to 1005 molecules used for the cDNA synthesis, the difference in the Ct values after preamplification and qRT-PCR is almost invisible. But if there are only 2 compared to 5 molecules pipetted into the preamplification reaction, the difference grows exponentially during the cycles (e.g., 14 cycles) of the preamplification process, and a huge difference in the expression levels respectively Ct values is detected after qRT-PCR. Assuming 100% efficiency of duplication during each cycle, after 14 cycles of preamplification 2 molecules become 16,384 molecules and 5 molecules become 6,103,515,625 molecules.
  • the sample was divided after cDNA synthesis into three reaction tubes for preamplification as in Example 1. After that, an identical volume was taken from each of the three preamplification reaction tubes and pipetted together into one reaction tube and mixed well for a single subsequent qRT-PCR (see Figure 2 ).
  • RNA For quantification of miR-371a-3p in serum samples, 6 ⁇ l of total RNA were reverse transcribed using the TaqMan ® microRNA RT Kit (Life Technologies/Thermo Fisher Scientific) and a primer pool consisting of 1 ⁇ l each of the stem loop primers for miR-371a-3p and miR-93-5p (for normalization) (Life Technologies/Thermo Fisher Scientific, assay IDs: 002124 (miR-371a-3p) and 000432 (miR-93-5p)).
  • RNA/miRNA in serum Because of the low concentration of RNA/miRNA in serum, a preamplification step was performed prior to qRT-PCR. First the sample was divided after cDNA synthesis into three reaction tubes for preamplification. The preamplification reaction consisted of 4 ⁇ l of the reverse transcription (RT) product, 1.12 ⁇ l assay (diluted 1:100) each of miR-371a-3p and miR-93-5p, 4 ⁇ l 5x Real Time ready cDNA Pre-Amp Master (Roche, Mannheim, Germany) and nuclease free water to add up to a total reaction volume of 20 ⁇ l. Preamplification was performed at 95°C for 1 min, followed by 14 cycles of 95°C for 15 s and 60° C for 4 min.
  • the qRT-PCR reaction consisted of 10 ⁇ l of the FASTstart Universal Probe Master (Roche, Mannheim, Germany), 1 ⁇ l of the specific assay, and nuclease free water in a total reaction volume of 20 ⁇ l.
  • qRT-PCR was performed on the 7500 Fast Real-Time PCR System (Life Technologies/Thermo Fisher Scientific) with the following cycling conditions: 10 min at 95°C, then 40 cycles of 15 s at 95°C and 1 min at 60°C.
  • Relative quantity (RQ) was calculated using the ⁇ Ct method.
  • results are shown in Figure 3 .
  • the mean miR-371a-3p expression in TIN patients was 30.75 RQ (relative quantity) with a standard deviation of 58.74.
  • the mean expression of the miRNA was 0.77 RQ with a standard deviation of 1.73.
  • miR-371a-3p can be used as a serum-based biomarker.
  • RQ 5 was chosen to differentiate between tumors and controls ( Dieckmann K.P. et al., 2016, Eur Urol doi:10.1016/j.eururo.2016.07.029 ).
  • the classical biomarkers ⁇ -fetoprotein (AFP), the ⁇ -subunit of human chorionic gonadotropin (bHCG) and lactate dehydrogenase (LDH) are used for the diagnosis of testicular germ cell tumors. These are normally not suitable for the detection of TIN. Even when all three classical markers were combined to one panel with the assumption that one increased classical marker constituted an overall positive score, only 1 of 10 (10%) TIN patients was detectable, compared to the 8 of 18 (44.4%) TIN patients detectable with the miR-371a-3p test in accordance with the present invention.
  • the possibility of detecting differences between TIN patients and healthy donors opens up new opportunities for the screening and/or monitoring of, e.g., risk groups for testicular cancer.
  • An earlier detection of TIN which will develop in all cases into testicular germ cell tumors, can protect patients against invasive cancer diseases and, therefore, guarantee a better quality of life and cost savings for the health care system.
  • the present invention provides the possibility for an early detection of patients with preliminary stage of germ cell tumors (TIN) in body fluids with an exact and reliable technique.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Claims (11)

  1. Procédé de détection de néoplasie intra-épithéliale testiculaire (TIN) chez un sujet, le procédé comprenant la détermination du taux d'expression de miR-371a-3p dans un échantillon de sérum sanguin du sujet, le taux d'expression de miR-371a-3p étant indicateur de la présence ou de l'absence de TIN chez le sujet.
  2. Procédé selon la revendication 1, dans lequel le procédé comprend les étapes consistant à :
    (i) fournir un lot A comprenant de l'ADNc isolé/obtenu à partir de l'échantillon de sérum sanguin, l'étape (i) comprenant les étapes consistant à :
    (ia) isoler de l'ARN à partir de l'échantillon de sérum sanguin ; et
    (ib) convertir en ADNc l'ARN isolé dans l'étape (ia), fournissant ainsi un lot A comprenant l'ADNc ;
    (ii) fournir trois ou plus de trois parties aliquotes du lot A fourni dans l'étape (i) et effectuer une réaction d'amplification en chaîne par polymérase (PCR) indépendante avec chacune des trois ou plus de trois parties aliquotes afin d'amplifier miR-371a-3p, fournissant ainsi trois ou plus de trois lots B comprenant le miR-371a-3p amplifié ; et
    (iii) mélanger des quantités égales des trois ou plus de trois lots B, fournissant ainsi un lot C, et déterminer le taux de miR-371a-3p dans le lot C par une méthode basée sur la PCR,
    le taux déterminé dans l'étape (iii) correspondant au taux d'expression de miR-371a-3p dans l'échantillon de sérum sanguin.
  3. Procédé selon la revendication 1, dans lequel le procédé comprend les étapes consistant à :
    (i) fournir un lot (A) comprenant de l'ADNc isolé/obtenu à partir de l'échantillon de sérum sanguin, l'étape (i) comprenant les étapes consistant à :
    (ia) isoler de l'ARN à partir de l'échantillon de sérum sanguin ; et
    (ib) convertir en ADNc l'ARN isolé dans l'étape (ia), fournissant ainsi un lot A comprenant l'ADNc ;
    (ii) fournir trois ou plus de trois parties aliquotes du lot A fourni dans l'étape (i) et effectuer une réaction d'amplification en chaîne par polymérase (PCR) indépendante avec chacune des trois ou plus de trois parties aliquotes afin d'amplifier miR-371a-3p, fournissant ainsi trois ou plus de trois lots B comprenant le miR-371a-3p amplifié ; et
    (iii) déterminer le taux de miR-371a-3p dans chacun des trois ou plus de trois lots B par une méthode basée sur la PCR et calculer la valeur moyenne des trois ou plus de trois taux de miR-371a-3p déterminés par la méthode basée sur la PCR,
    la valeur moyenne calculée dans l'étape (iii) correspondant au taux d'expression de miR-371a-3p dans l'échantillon de sérum sanguin.
  4. Procédé selon l'une quelconque des revendications 1 à 3, dans lequel un taux d'expression de miR-371a-3p qui est augmenté par rapport à un témoin est indicateur de la présence de TIN chez le sujet.
  5. Procédé selon l'une quelconque des revendications 1 à 3, dans lequel un taux d'expression de miR-371a-3p qui est supérieur à une valeur seuil prédéfinie est indicateur de la présence de TIN chez le sujet.
  6. Procédé selon l'une quelconque des revendications 1 à 5, dans lequel, dans l'étape (ii), trois partie aliquotes de lot A sont fournies.
  7. Procédé selon l'une quelconque des revendications 1 à 6, dans lequel la méthode basée sur la PCR est la PCR quantitative en temps réel (qRT-PCR) ou la PCR numérique (dPCR).
  8. Utilisation de miR-371a-3p en tant que biomarqueur basé sur sérum sanguin pour la détection de néoplasie intra-épithéliale testiculaire (TIN).
  9. Utilisation d'au moins une amorce spécifique de miR-371a-3p et/ou une sonde spécifique de miR-371a-3p pour la détection de néoplasie intra-épithéliale testiculaire (TIN) conformément au procédé selon l'une quelconque des revendications 1 à 6.
  10. Utilisation d'un kit comprenant au moins une amorce spécifique de miR-371a-3p et/ou une sonde spécifique de miR-371a-3p pour la détection de néoplasie intra-épithéliale testiculaire (TIN) conformément au procédé selon l'une quelconque des revendications 1 à 6.
  11. Utilisation selon la revendication 10, dans lequel le kit comprend un moyen pour isoler de l'ARN à partir d'un échantillon de sérum sanguin et/ou un moyen pour convertir en ADNc l'ARN isolé à partir de l'échantillon de sérum sanguin.
EP17800438.8A 2016-11-02 2017-11-02 Détection précoce de stades préliminaires de tumeurs de cellules germinales testiculaires Active EP3535417B9 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16196813 2016-11-02
PCT/EP2017/078079 WO2018083186A1 (fr) 2016-11-02 2017-11-02 Détection précoce de stades préliminaires de tumeurs de cellules germinales testiculaires

Publications (3)

Publication Number Publication Date
EP3535417A1 EP3535417A1 (fr) 2019-09-11
EP3535417B1 true EP3535417B1 (fr) 2023-06-07
EP3535417B9 EP3535417B9 (fr) 2023-10-04

Family

ID=57223558

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17800438.8A Active EP3535417B9 (fr) 2016-11-02 2017-11-02 Détection précoce de stades préliminaires de tumeurs de cellules germinales testiculaires

Country Status (9)

Country Link
US (1) US11643690B2 (fr)
EP (1) EP3535417B9 (fr)
JP (2) JP7391367B2 (fr)
CN (1) CN109890979B (fr)
AU (1) AU2017353410B2 (fr)
CA (1) CA3038010A1 (fr)
ES (1) ES2952061T3 (fr)
PL (1) PL3535417T3 (fr)
WO (1) WO2018083186A1 (fr)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101363057B (zh) 2008-09-09 2011-11-09 浙江理工大学 一种生物样本中miRNA绝对表达量的检测方法
US20120107825A1 (en) * 2010-11-01 2012-05-03 Winger Edward E Methods and compositions for assessing patients with reproductive failure using immune cell-derived microrna
ES2967272T3 (es) * 2011-11-30 2024-04-29 Bullerdiek Joern Expresión de miARNs en tejido placentario
CN104844566B (zh) * 2014-12-12 2018-05-18 合肥中科普瑞昇生物医药科技有限公司 一种新型结构的激酶抑制剂
WO2016174199A1 (fr) 2015-04-29 2016-11-03 Mirdetect Gmbh Génération de molécules d'acide nucléique
US10136952B2 (en) * 2016-06-16 2018-11-27 Zimmer, Inc. Soft tissue balancing in articular surgery

Also Published As

Publication number Publication date
US11643690B2 (en) 2023-05-09
WO2018083186A1 (fr) 2018-05-11
JP2022088555A (ja) 2022-06-14
EP3535417A1 (fr) 2019-09-11
EP3535417B9 (fr) 2023-10-04
CN109890979A (zh) 2019-06-14
US20200056243A1 (en) 2020-02-20
ES2952061T9 (es) 2023-11-02
ES2952061T3 (es) 2023-10-26
CA3038010A1 (fr) 2018-05-11
AU2017353410A1 (en) 2019-04-11
JP2019532653A (ja) 2019-11-14
AU2017353410B2 (en) 2023-04-13
CN109890979B (zh) 2023-06-16
JP7391367B2 (ja) 2023-12-05
PL3535417T3 (pl) 2023-10-02

Similar Documents

Publication Publication Date Title
EP2732052B1 (fr) Profilage diagnostique de microarn dans le lymphome cutané à cellules t (ctcl)
US20200123606A1 (en) Rt-qpcr method for direct quantitative detection of circulating mirna
CN116761899A (zh) 结直肠癌分子分型及生存风险基因群及诊断产品和应用
Butz et al. Technical aspects related to the analysis of circulating microRNAs
US20230304081A1 (en) Primer and probe design method, detection composition, and kit for mirna detection
CN107299129B (zh) 循环核酸作为乳腺癌生物标志物的应用
CN106148500B (zh) 一体化微小rna荧光定量检测试剂盒及其应用
EP3289095B1 (fr) Génération de molécules d'acide nucléique
EP3535417B9 (fr) Détection précoce de stades préliminaires de tumeurs de cellules germinales testiculaires
CN110295232B (zh) 用于结直肠癌的microRNA生物标记物
JP6871271B2 (ja) Ｄｌｂｃｌを分類するための方法および組成物
WO2023074135A1 (fr) Procédé et kit de réactifs pour aider à déterminer le pronostic du cancer pulmonaire
EP3719144A1 (fr) Mir-151a-3p en tant que contrôle endogène universel pour la normalisation d'un chargement d'exosomes
RU2469323C2 (ru) Способ диагностики рака мочевого пузыря (варианты) и набор для его осуществления
Al-Temimi et al. EVALUATION OF MICRORNA-21 IN INVASIVE DUCTAL CARCINOMA IN COMPARISON TO CLINICOPATHOLOGICAL STATUS BY STEM-LOOP RT-PCR PROCEDURE.
CN111334576A (zh) 一种与肝癌索拉非尼耐药相关的miRNA标志物及其应用
TW201335375A (zh) 提升檢測ｋｒａｓ編碼子１２及１３突變之靈敏度及專一性之方法
CN110656162A (zh) 一种循环miR-1290的检测方法

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190516

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40013273

Country of ref document: HK

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20221028

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: AT

Ref legal event code: REF

Ref document number: 1575151

Country of ref document: AT

Kind code of ref document: T

Effective date: 20230615

Ref country code: DE

Ref legal event code: R096

Ref document number: 602017069761

Country of ref document: DE

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230516

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: CH

Ref legal event code: PK

Free format text: BERICHTIGUNG B9

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2952061

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20231026

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230607

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230907

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1575151

Country of ref document: AT

Kind code of ref document: T

Effective date: 20230607

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230607

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230607

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230607

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230607

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230908

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230607

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20231122

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230607

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20231123

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20231215

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231007

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230607

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230607

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230607

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231009

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20231007

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230607

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230607

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230607

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20231024

Year of fee payment: 7

Ref country code: IT

Payment date: 20231130

Year of fee payment: 7

Ref country code: FR

Payment date: 20231124

Year of fee payment: 7

Ref country code: DE

Payment date: 20231123

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PL

Payment date: 20231024

Year of fee payment: 7

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602017069761

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230607

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230607

26N No opposition filed

Effective date: 20240308

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230607